Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of “Moderate Buy” by Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.14.

Several research firms recently issued reports on CATX. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt acquired 12,829 shares of the company’s stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. This represents a 35.66 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Johan M. Spoor acquired 14,500 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now owns 152,072 shares in the company, valued at approximately $574,832.16. The trade was a 10.54 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 67,570 shares of company stock worth $256,789 in the last ninety days. 3.52% of the stock is owned by company insiders.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter worth about $57,000. US Bancorp DE raised its stake in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics in the second quarter worth $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the second quarter valued at $118,000. Finally, Intech Investment Management LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter worth about $137,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Trading Up 4.2 %

NYSE:CATX opened at $3.19 on Wednesday. The business’s fifty day moving average is $6.49 and its 200 day moving average is $10.64. Perspective Therapeutics has a 52-week low of $2.70 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million during the quarter. Research analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.